PHBBF (Pharmaron Beijing Co) Retained Earnings: $1,163 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHBBF Pharmaron Beijing Co Ltd PHBBF
90 GF Score
Price $1.93
GF Value $1.67
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Retained Earnings?

Pharmaron Beijing Co PHBBF 90 Retained Earnings is $1,163 Mil as of Mar. 2026. GuruFocus rates PHBBF with a GF Score™ of 90/100 and a GF Value™ of $1.67. The stock has 9 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Pharmaron Beijing Co's retained earnings for the quarter that ended in Mar. 2026 was $1,163 Mil.

Pharmaron Beijing Co's quarterly retained earnings increased from Sep. 2025 ($1,015 Mil) to Dec. 2025 ($1,090 Mil) and increased from Dec. 2025 ($1,090 Mil) to Mar. 2026 ($1,163 Mil).

Pharmaron Beijing Co's annual retained earnings increased from Dec. 2023 ($729 Mil) to Dec. 2024 ($885 Mil) and increased from Dec. 2024 ($885 Mil) to Dec. 2025 ($1,090 Mil).


Pharmaron Beijing Co  (OTCPK:PHBBF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Pharmaron Beijing Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Retained Earnings Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 505.83 595.61 728.90 884.91 1,090.24

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 930.89 945.83 1,015.09 1,090.24 1,162.80
PHBBF
90GF Score
Pharmaron Beijing Co Ltd PHBBF
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $1,163 Mil mean?
Pharmaron Beijing Co (PHBBF) has a Retained Earnings of $1,163 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Retained Earnings too high?
Pharmaron Beijing Co's current Retained Earnings is $1,163 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Retained Earnings compare to VRTX and REGN?
Pharmaron Beijing Co's Retained Earnings of $1,163 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Retained Earnings is $1,163 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Retained Earnings of $1,163 Mil. The stock's GF Value™ is $1.67, compared to a current price of $1.93 — trading 15.6% above its estimated fair value. The current Retained Earnings is $1,163 Mil. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Retained Earnings is $1,163 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of $1.93 is trading 15.6% above its estimated GF Value™ of $1.67.

Key valuation signals for PHBBF:

  • Retained Earnings: $1,163 Mil
  • GF Value™: $1.67 vs. price of $1.93 (15.6% above fair value)
  • GF Score™: 90/100 with 9 warning signs

No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score

Get the complete analysis for PHBBF

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.67
GF Value